JP2014521744A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521744A5
JP2014521744A5 JP2014526078A JP2014526078A JP2014521744A5 JP 2014521744 A5 JP2014521744 A5 JP 2014521744A5 JP 2014526078 A JP2014526078 A JP 2014526078A JP 2014526078 A JP2014526078 A JP 2014526078A JP 2014521744 A5 JP2014521744 A5 JP 2014521744A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cycloalkyl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521744A (ja
JP5903162B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/050051 external-priority patent/WO2013025424A1/en
Publication of JP2014521744A publication Critical patent/JP2014521744A/ja
Publication of JP2014521744A5 publication Critical patent/JP2014521744A5/ja
Application granted granted Critical
Publication of JP5903162B2 publication Critical patent/JP5903162B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526078A 2011-08-17 2012-08-09 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体 Expired - Fee Related JP5903162B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17
US61/524,462 2011-08-17
PCT/US2012/050051 WO2013025424A1 (en) 2011-08-17 2012-08-09 A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

Publications (3)

Publication Number Publication Date
JP2014521744A JP2014521744A (ja) 2014-08-28
JP2014521744A5 true JP2014521744A5 (enExample) 2015-09-24
JP5903162B2 JP5903162B2 (ja) 2016-04-13

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526078A Expired - Fee Related JP5903162B2 (ja) 2011-08-17 2012-08-09 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体

Country Status (30)

Country Link
US (1) US8431706B2 (enExample)
EP (1) EP2744806B1 (enExample)
JP (1) JP5903162B2 (enExample)
KR (1) KR101570624B1 (enExample)
CN (1) CN103687856B (enExample)
AP (1) AP3589A (enExample)
AR (1) AR087451A1 (enExample)
AU (1) AU2012295372A1 (enExample)
BR (1) BR112014003079A2 (enExample)
CA (1) CA2843474C (enExample)
CL (1) CL2014000357A1 (enExample)
CO (1) CO6880069A2 (enExample)
CR (1) CR20140052A (enExample)
DO (1) DOP2014000018A (enExample)
EA (1) EA022165B1 (enExample)
EC (1) ECSP14013211A (enExample)
ES (1) ES2578165T3 (enExample)
GT (1) GT201400022A (enExample)
IL (1) IL230635A (enExample)
IN (1) IN2014MN00191A (enExample)
MA (1) MA35351B1 (enExample)
MX (1) MX2014001832A (enExample)
PE (1) PE20140831A1 (enExample)
PH (1) PH12014500366A1 (enExample)
SG (1) SG11201401793PA (enExample)
TN (1) TN2014000058A1 (enExample)
TW (1) TWI537262B (enExample)
UA (1) UA110983C2 (enExample)
WO (1) WO2013025424A1 (enExample)
ZA (1) ZA201400705B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928097A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
US20220213051A1 (en) * 2019-05-31 2022-07-07 Hyundai Pharm Co., Ltd. Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
WO2021083270A1 (zh) * 2019-10-31 2021-05-06 中国石油化工股份有限公司 负载型催化剂及其制备方法和应用
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
IL157093A0 (en) * 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4875978B2 (ja) * 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Similar Documents

Publication Publication Date Title
JP2014521744A5 (enExample)
JP2015512931A5 (enExample)
JP2013542218A5 (enExample)
JP2011500550A5 (enExample)
JP2013537203A5 (enExample)
JP2014508811A5 (enExample)
JP2013523733A5 (enExample)
JP2015500843A5 (enExample)
JP2011105738A5 (enExample)
JP2013032389A5 (enExample)
JP2011518833A5 (enExample)
JP2012533546A5 (enExample)
JP2012506896A5 (enExample)
JP2011137045A5 (enExample)
JP2015505296A5 (enExample)
JP2011037841A5 (enExample)
JP2013512277A5 (enExample)
JP2014526533A5 (enExample)
JP2013544860A5 (enExample)
JP2010521516A5 (enExample)
JP2013532130A5 (enExample)
JP2011088926A5 (enExample)
JP2010132677A5 (enExample)
JP2013542981A5 (enExample)
JP2016528273A5 (enExample)